TWINRIX JERINGA PRECARGADA

( ARTG ) TWINRIX (720/20) is indicated for active immunisation against hepatitis A and hepatitis B virus infection in adults and children from 1 year of age. TWINRIX Junior (360/10) is indicated for use in children aged 1 to 15 years.,Immunisation against hepatitis A is recommended in the following individuals : Travellers: Persons travelling to areas of intermediate or high endemicity for hepatitis A. This includes all developing countries.,Armed Forces: Armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of HAV infection.,Persons for whom hepatitis A is an occupational hazard or for whom there is an increased risk of transmission. These include:,employees in day-care centres particularly in situations where children have not been toilet trained,teachers and other close contacts of the intellectually disabled,staff and residents of residential facilities for the intellectually disabled,healthcare workers and teachers in remote Aboriginal and Torres Strait Islander communities,nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units,sewerage workers,food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers,Homosexual men: Increased incidence of hepatitis A infection among homosexual males suggests that the disease may be sexually transmitted in this group.,Contacts of infected persons: Since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. The use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin.,Specific population groups known to have a higher incidence of hepatitis A: eg. Australian Aboriginals, those in settings with recognised community-wide HAV epidemics.,Individuals with chronic liver disease and recipients of liver transplants, as hepatitis A infection is likely to be more severe in these groups. Many injecting drug users will have pre-existing liver disease from hepatitis B or hepatitis C infection.,Recipients of blood products, such as Factor VIII concentrates.,Immunisation against hepatitis B is recommended in the following individuals:,Persons for whom hepatitis B is an occupational hazard or for whom there is an increased risk of transmission. These include:,healthcare workers directly involved in patient care, or in the handling of human blood or tissue,embalmers,staff and residents of residential facilities for the intellectually disabled,inmates of long term correctional facilities and staff of correctional facilities,Individuals with chronic liver disease and/or hepatitis C.,Haemodialysis patients and recipients of certain blood products such as Factor VIII concentrates.,Sexually active homosexual men and persons with multiple sexual partners: e.g. clients of STD (sexually transmitted disease) clinics. Sexual risk occurs in susceptible (anti-HBs negative) partners of HBV carriers and patients with acute hepatitis B.,Abusers of injectable drugs.,Close residential contacts of deinstitutionalised intellectually disabled individuals who are HBV carriers.,Household contacts of patients with acute hepatitis B and chronic hepatitis B carriers.,Others in whom vaccination against hepatitis B might be justified,Police and members of the armed forces,Travellers to areas of high endemicity for hepatitis B,Participants in contact sportsTwinrix (720/20) is indicated for active immunisation against hepatitis A and hepatitis B virus infection in adults and children from 1 year of age. Twinrix Junior (360/10) is indicated for use in children aged 1 to 15 years.